The current stock price of TIVC is 1.26 USD. In the past month the price decreased by -14.86%. In the past year, price decreased by -68.55%.
ChartMill assigns a fundamental rating of 2 / 10 to TIVC. TIVC has a great financial health rating, but its profitability evaluates not so good.
Over the last trailing twelve months TIVC reported a non-GAAP Earnings per Share(EPS) of -9.87. The EPS increased by 88.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -120.5% | ||
| ROE | -134.25% | ||
| Debt/Equity | 0 |
Tivic Health Systems, Inc. operates as a bio-electronic health-tech company, which develops micro current therapy solutions for chronic diseases and conditions. The company is headquartered in Fremont, California and currently employs 7 full-time employees. The company went IPO on 2021-11-11. The Company’s biopharma program is focused on advancing its drug product candidate, Entolimod, into manufacturing, conducting process validation utilizing the output of such manufacturing with the intent of selling the biologic compounds either inside or outside the United States. The Company’s bioelectronic program is focused on developing non-invasive medical devices that influence biologic functions associated with various diseases and conditions. The company has an over-the-counter device, ClearUP, that treats sinus pain and pressure. The Company’s Toll-like Receptor 5 (TLR5) program’s lead product candidate is the late-stage TLR5 agonist, Entolimod, to treat acute radiation syndrome (ARS) and for remediating side effects of medical radiation and chemotherapy. The firm offers contract development and manufacturing organization through its subsidiary Velocity Bioworks, Inc.
TIVIC HEALTH SYSTEMS INC
47685 Lakeview Blvd
Fremont CALIFORNIA US
Employees: 7
Phone: 18882766888
Tivic Health Systems, Inc. operates as a bio-electronic health-tech company, which develops micro current therapy solutions for chronic diseases and conditions. The company is headquartered in Fremont, California and currently employs 7 full-time employees. The company went IPO on 2021-11-11. The Company’s biopharma program is focused on advancing its drug product candidate, Entolimod, into manufacturing, conducting process validation utilizing the output of such manufacturing with the intent of selling the biologic compounds either inside or outside the United States. The Company’s bioelectronic program is focused on developing non-invasive medical devices that influence biologic functions associated with various diseases and conditions. The company has an over-the-counter device, ClearUP, that treats sinus pain and pressure. The Company’s Toll-like Receptor 5 (TLR5) program’s lead product candidate is the late-stage TLR5 agonist, Entolimod, to treat acute radiation syndrome (ARS) and for remediating side effects of medical radiation and chemotherapy. The firm offers contract development and manufacturing organization through its subsidiary Velocity Bioworks, Inc.
The current stock price of TIVC is 1.26 USD. The price decreased by -1.56% in the last trading session.
TIVC does not pay a dividend.
TIVC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
TIVC stock is listed on the Nasdaq exchange.